Last reviewed · How we verify

Second-line Antipsychotics

Dr. Inge Winter · Phase 3 active Small molecule

Second-line antipsychotics work by blocking dopamine receptors in the brain, reducing psychotic symptoms.

Second-line antipsychotics work by blocking dopamine receptors in the brain, reducing psychotic symptoms. Used for Treatment of schizophrenia, Treatment of bipolar disorder.

At a glance

Generic nameSecond-line Antipsychotics
SponsorDr. Inge Winter
Drug classSecond-line antipsychotic
TargetD2 receptor
ModalitySmall molecule
Therapeutic areaPsychiatry
PhasePhase 3

Mechanism of action

They achieve this by selectively binding to D2 receptors, which are involved in the regulation of movement and emotion. This blockade helps to alleviate symptoms of schizophrenia and other psychotic disorders.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results